Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021424 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer
A Phase 1 study, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00021424: Completed Phase 1 study, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
NCT00021424 is a Phase 1 study that has completed, run by National Institute on Deafness and Other Communication Disorders (NIDCD). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021424, a Phase 1 study, has completed, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV head and neck cancer.
Interventions
- BIOLOGICAL recombinant fowlpox-TRICOM vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Phase | Phase 1 |
What the finished NCT00021424 record still lists
NCT00021424 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which recombinant fowlpox-TRICOM vaccine is the first listed.
NCT00021424 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00021424 about?
NCT00021424 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV head and neck cancer.
What is the current status of trial NCT00021424?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-06.
What interventions are being tested in trial NCT00021424?
The interventions under investigation include: recombinant fowlpox-TRICOM vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00021424?
This trial is sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD), which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia